Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Total Current Liabilities for 7 consecutive years, with $7.0 million as the latest value for Q1 2025.
- Quarterly Total Current Liabilities rose 104.42% to $7.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Mar 2025, up 104.42% year-over-year, with the annual reading at $4.9 million for FY2024, 23.78% up from the prior year.
- Total Current Liabilities hit $7.0 million in Q1 2025 for Benitec Biopharma, up from $3.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $7.0 million in Q1 2025 to a low of $1.4 million in Q2 2021.
- Historically, Total Current Liabilities has averaged $3.4 million across 5 years, with a median of $3.1 million in 2024.
- Biggest five-year swings in Total Current Liabilities: surged 218.36% in 2021 and later plummeted 46.24% in 2024.
- Year by year, Total Current Liabilities stood at $2.5 million in 2021, then grew by 0.36% to $2.5 million in 2022, then skyrocketed by 130.86% to $5.7 million in 2023, then tumbled by 46.24% to $3.1 million in 2024, then skyrocketed by 127.45% to $7.0 million in 2025.
- Business Quant data shows Total Current Liabilities for BNTC at $7.0 million in Q1 2025, $3.1 million in Q4 2024, and $4.6 million in Q3 2024.